CHEST Guidelines-Different-ICSs-and-the-Risk-of Pneumonia

Different-ICSs-and-the-Risk-of Pneumonia_ches

Pdf Summary

A letter to the editor discusses a recent study by Suissa et al., which found an increased risk of severe pneumonia associated with the initiation of COPD treatment using Long-Acting Muscarinic Antagonist-Long-Acting Beta2-Agonist-Inhaled Corticosteroid (LAMA-LABA-ICS) compared to LAMA-LABA treatment. The authors of the letter, led by Cheng-Yi Wang, and associated with medical institutions in Taiwan, raise concerns about the varying risks of pneumonia linked to different inhaled corticosteroids (ICS) used in these treatments. They highlight that previous studies have shown that fluticasone-based ICS treatments carry a higher risk of pneumonia than those based on budesonide. Their own study found significant pneumonia risk when fluticasone was used but not with other corticosteroids like budesonide or beclomethasone. They emphasize the need for further studies to clarify these differences to better tailor COPD treatments to individual patient needs.<br /><br />In response, Suissa and colleagues acknowledge Wang et al.’s points and mention their own findings from a study with over 160,000 COPD patients, confirming a higher risk of serious pneumonia with fluticasone use. This dialogue underscores the importance of investigating the differential impact of ICS types on pneumonia risk in COPD treatments, highlighting the critical need for personalized medical approaches to reduce adverse effects while managing COPD effectively.

Keywords

COPD treatment

severe pneumonia

LAMA-LABA-ICS

inhaled corticosteroids

fluticasone

budesonide

pneumonia risk

personalized medicine

Suissa study

Cheng-Yi Wang